Polyphenols as Potential Protectors against Radiation-Induced Adverse Effects in Patients with Thoracic Cancer
- PMID: 37173877
- PMCID: PMC10177176
- DOI: 10.3390/cancers15092412
Polyphenols as Potential Protectors against Radiation-Induced Adverse Effects in Patients with Thoracic Cancer
Abstract
Radiotherapy is one of the standard treatment approaches used against thoracic cancers, occasionally combined with chemotherapy, immunotherapy and molecular targeted therapy. However, these cancers are often not highly sensitive to standard of care treatments, making the use of high dose radiotherapy necessary, which is linked with high rates of radiation-induced adverse effects in healthy tissues of the thorax. These tissues remain therefore dose-limiting factors in radiation oncology despite recent technological advances in treatment planning and delivery of irradiation. Polyphenols are metabolites found in plants that have been suggested to improve the therapeutic window by sensitizing the tumor to radiotherapy, while simultaneously protecting normal cells from therapy-induced damage by preventing DNA damage, as well as having anti-oxidant, anti-inflammatory or immunomodulatory properties. This review focuses on the radioprotective effect of polyphenols and the molecular mechanisms underlying these effects in the normal tissue, especially in the lung, heart and esophagus.
Keywords: normal tissue; polyphenols; radioprotection; radiotherapy-induced adverse effects; thoracic cancers.
Conflict of interest statement
LJD has, outside of the submitted work, shares in the companies Convert Pharmaceuticals and LivingMed Biotech, he is co-inventor of a non-issue, non-licensed patent on LSRT (N2024889). The other authors declare no conflict of interest.
Figures
Similar articles
-
Parthenolide Selectively Sensitizes Prostate Tumor Tissue to Radiotherapy while Protecting Healthy Tissues In Vivo.Radiat Res. 2017 May;187(5):501-512. doi: 10.1667/RR14710.1. Epub 2017 Mar 3. Radiat Res. 2017. PMID: 28398879
-
Effects of traditional oriental medicines as anti-cytotoxic agents in radiotherapy.Oncol Lett. 2017 Jun;13(6):4593-4601. doi: 10.3892/ol.2017.6042. Epub 2017 Apr 18. Oncol Lett. 2017. PMID: 28599460 Free PMC article.
-
Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?Int J Mol Sci. 2018 Dec 21;20(1):24. doi: 10.3390/ijms20010024. Int J Mol Sci. 2018. PMID: 30577587 Free PMC article. Review.
-
Melatonin as an adjuvant in radiotherapy for radioprotection and radiosensitization.Clin Transl Oncol. 2019 Mar;21(3):268-279. doi: 10.1007/s12094-018-1934-0. Epub 2018 Aug 22. Clin Transl Oncol. 2019. PMID: 30136132 Review.
-
Normal tissue protection for improving radiotherapy: Where are the Gaps?Transl Cancer Res. 2012 Jun;1(1):35-48. Transl Cancer Res. 2012. PMID: 22866245 Free PMC article.
Cited by
-
Revolutionizing radiotherapy: gold nanoparticles with polyphenol coating as novel enhancers in breast cancer cells-an in vitro study.Discov Nano. 2025 Jan 15;20(1):10. doi: 10.1186/s11671-025-04186-x. Discov Nano. 2025. PMID: 39812897 Free PMC article.
References
-
- Bradley J., Movsas B. In: Radiation Pneumonitis and Esophagitis in Thoracic Irradiation, in Radiation Toxicity: A Practical Guide. Small W., Woloschak G.E., editors. Springer; Boston, MA, USA: 2006. pp. 43–64. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources